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Synthesis of Colibactin Pyrrolidono[3,4-d]pyridones via  
Regioselective C(sp3)–H Activation 
Agron Ilazi, Bin Huang, Valery de Almeida Campos, and Karl Gademann* 
The synthesis of pyrrolidono[3,4-d]pyridones  of relevance to putative genotoxic 
colibactin structures featuring a doubly conjugated 1,6-Michael acceptor system is 
reported. We investigated and implemented a highly selective Pd-catalyzed C(sp3)-
H activation reaction as a key step and further functionalized the pyridone core. 
Evaluating the role of this structural unit of relevance the colibactin, we found that 
this structure displayed a high degree of stability towards both acidic conditions 
and nucleophiles. 
 
The term ‘human microbiota’ refers to a wide range of different micro-
organisms such as bacteria, fungi, and viruses residing in and on the 
human body and have been implied as human’s second genome.[1] Lit-
tle is known about their inter-kingdom interaction and their effect on 
human health or disease progression.[2] Recently, the bacteria Helico-
bacter pylori and Klebsiella oxytoca have been identified to induce coli-
tis, albeit by different mechanisms.[3] Over a decade ago, the Oswald 
group reported that certain commensal and extra-intestinal E. coli 
strains of the phylogenetic group B2 can cause megalocytosis and cell 
cycle arrest.[4] These scientists identified and linked cytotoxicity to a 
54 kilobase pks genomic island harboring a hybrid non ribosomal pep-
tide synthetase-polyketide synthase NRPS-PKS and provided evidence 
for the whole gene cluster linked to its cytotoxicity.[4]  
 
Figure 1. Natural compounds isolated from the clb E. coli strain 
of putative relevance to the (pre)-colibactin structure of pKs is-
land. 
Over the last fifteen years, the isolation and characterization of the 
small molecule compounds resulting from this cluster (the so-called 
(pre)-colibactins) proved to be challenging, presumably due to their in-
stability, difficulties in heterologous expression, and fermentation (Fig-
ure 1).[5] A number of metabolites such as the pyridone 1, the mono-
thiazole substituted 2, the bisthiazole substituted 3, and the  complex 
macrocycle 4 have been isolated.[5] Furthermore, the lactam 5 was 
proposed to bear the colibactin warhead [5a] and the recently pro-
posed active genotoxic metabolite 6 [5i, h] have been characterized and 
linked to the pks island and/or its mutants. Seminal synthetic and reac-
tivity studies by Herzon,Crawford, and their co-workers led them to 
conclude that compounds similar to lactam 6, albeit monomeric, and 
not pyridones such as 1-3 alkylate DNA, with the pyridones being sta-
ble.[5k]  All these structures feature a cyclopropyl ring (Figure 1, high-
lighted) in conjugation with 1,4-or 1,6-Michael acceptors, thereby 
likely increasing their electrophilic character. Another feature of these 
compounds includes a prodrug mechanism, where a clb encoded pep-
tidase cleaves the N-myristoyl-D-asparagine moiety to generate com-
pounds with higher activity and reactivity.[6, 7] In the context of recent 
studies of pyridones as neuritogenic compounds by us and others,[8] 
and the prevalence of pyridone containing natural products and phar-
macophores, [9]   we directed our attention to pyrrolidono[3,4-d]pyr-
idones 1-3, as these complex heterocyclic compounds have incorpo-
rated the cyclopropyl ring in a unique double 1,6-relationship through 
conjugation, rendering them structurally interesting Michael accep-
tors. In addition, Michael acceptors and other covalent modifiers 
gained strong interest in drug discovery efforts over the last years.[10] 
In addition to these biological questions and structural requirements 
for addition, we were also interested in identifying a novel route to-
wards these compounds, which should facilitate the access to the target 
structure and derivatives for chemical and biological evaluation. 
Therefore, we report on a novel access to this class of compounds via a 
regioselective, Pd-catalyzed C(sp3)–H activation approach.[11] 
Scheme  1 C–H functionalization of cyclopropyl amides 
via Pd catalysis. 
 
The development and application of powerful C-H activation method-
ologies has gained tremendous interest and been successfully imple-
 
mented in many synthetic endeavors.[12] Promising literature prece-
dents for C-H functionalization of cyclopropyl amides (Scheme 1) led 
us to examine this synthetic approach. Fagnou and co-authors demon-
strated the superiority of a soluble organic additives like pivaloic acid 
for C–H activation protocols and his group established a C–H function-
alization of cyclopropyl carbamates leading to quinolines after oxida-
tion.[13] The group of Charette observed in 2013 that cyclopropyl ben-
zamides are less prone to ring-opening in the presence of external ba-
ses.[14] Cramer and coworkers investigated the effect of ligands and a 
1:1 ratio between methine and methylene C–H bond cleavage was ob-
tained with triphenylphosphine as ligand and 1-adamantanecarbox-
ylate as base. [15] In all previous literature studies, the desired five 
membered compounds were never obtained as major products. From 
all these observations, the following challenges had to be overcome in 
the context of this study: (1) The different electronic nature of pyridine 
amides when compared to benzene derivatives; (2) use of chloro- in-
stead of more reactive bromo-precursors, (3) successfully addressing 
the regioselectivity bias, and favor methine over methylene C–H acti-
vation; and (4) suppressing the inherent susceptibility of the cyclopro-
pyl group for ring opening. The chloro substituent was preferred over 
the more reactive bromo or iodo substituents,  as we sought to first in-
troduce amide or carboxylate groups by cross coupling or halogen-
metal exchange on the C–Br bond before the C–H activation step (vide 
infra). 
Scheme  2. Investigation of the C-H activation reaction on a 
model substrate (TMB = 3,4,5–trimethoxybenzyl). 
 
Table 1. Conditions for the key C-H activation reaction on a 
model substrate. 




(isolated yield %) 
1 PCy3•HBF4 21 1:5.5:0 (83%) 
2 IPrCl 16 1:2:0 
3 SIPrBF4 16 1.2:1:0 (86%) 
4b IAdBF4 17 2.2:0:1 (45%) 
5 IPrBIANCl 16 1:2.8:n.d 
6 L1 22 n.d 
7 L2 22 n.d 
a ratio determined by analysis reaction mixtures by 1H NMR spectros-
copy. b105 °C 1h and 110 °C 15 h  
The challenges listed above were first investigated in the context of a 
model substrate, which was synthesized in two steps. Reductive ami-
nation of 3,4,5-trimethoxybenzaldehyde 7 with cyclopropyl amine us-
ing triacetoxyborohydride gave the secondary amine 8 in 72% yield 
[16]. 4-Chloronicotinic acid 9 was converted in situ to the correspond-
ing acyl chloride ((COCl)2, cat. DMF), subsequent addition of 8 in the 
presence of triethylamine furnished amide 10 (91%).[18] With the in-
termediate 10 in hand, the stage for the C-H functionalization was set 
and the results are summarized in Table 1 Literature reports suggest 
that the role of the ligand has the strongest influence on the outcome of 
the reaction, while other parameters such as Pd source, base, additive, 
and solvent were based on recent findings. [14-15] The following pa-
rameters were set, Pd2dba3, Cs2CO3, CsOPiv as soluble organic base, tol-
uene as solvent and generally a temperature of 100 °C was kept, since 
it was sufficient for the reactivity. The electron rich PCy3•HBF4 gave an 
inseparable mixture of 11a:11b (1:5.5, 83%) in favor of the undesired 
six membered ring (entry 1, table 1), and no formation of the seven 
membered ring derivative 11c was observed. Despite the strong C–Cl 
bond of the precursor 10, oxidative addition was taking place at 100 °C. 
The electron withdrawing nitrogen atom activates the γ− position, 
thereby facilitating the oxidative addition. N-Heterocyclic carbenes 
were investigated next: the ratio dropped to 1:2 using  the IPrCl ligand, 
and by using the SIPrBF4 ligand, the five membered ring compound 11a 
dominated (1.2:1, 86%) without any ring opening observed (entries 2-
3, table 1). This increase prompted us to evaluate other NHC carbenes 
and the IAdBF4 ligand was selective towards 11a with 31% along with 
the opened ring compound 11c in 14% as separable compounds (entry 
4, table 1), albeit in the presence of other by-products. The last ligand 
from the NHC series, the IPrBIANCl led to preferred formation of the 
six membered ring 11b (entry 5, table 1). The TADDOL based phos-
phonite and phosphoroamidite ligands did not yield products (entries 
6-7, table 1) and in general NHC ligands proved superior in this screen-
ing, although no clear trends could be obtained with respect to their 
electronic and steric properties. 
Scheme  3. Synthesis of Colibactin Pyrrolidono[3,4-d]pyr-




We then proceeded to the desired substrate with the insight gained 
from the C–H activation screening (Scheme 3). 2,4-Dichloropyridine 12 
was found as a suitable starting material and nucleophilic aromatic 
substitution with 2-(trimethylsilyl)ethanol provided the 2-substitued 
product 13 with high regioselectivity and 77% yield.[18] Selective or-
tho bromination was achieved with 1,3-dibromo-5,5-dimethylhydan-
toin (DBDMH) and catalytic AgNO3 to yield dihalogenated pyridine 14 
(77%). Silver(I) was found to shorten the reaction time significantly. 
Mg halogen exchange following the procedure of Knochel[19] and sub-
sequent quenching of the magnesiated species with solid carbon diox-
ide yielded the acid 15 (>95%). Propylphosphonic anhydride (T3P) 
mediated coupling of the acid 15 and secondary amine 8 furnished the 
amide 16 in 95% yield. The Arduengo carbene IAd was selected as the 
optimal ligand, as it provided higher selectivity towards the desired 
five membered ring in this substrate (data not shown) and resulting in 
easier purification. On the other side, the five membered ring was dom-
inating with the SIPrCl ligand, but other by-products were accompany-
ing the transformation with this ligand. To this goal, cyclopropyl amide 
16 was reacted with Pd2dba3, Cs2CO3, CsOPiv, and IAdBF4 in toluene at 
a reaction temperature of 100 °C. The desired compound was formed 
exclusively according to analysis of the crude reaction mixture by 1H-
NMR spectroscopy, and after purification, bicyclic pyrrolidono[3,4-
d]pyridine 17 was isolated in 82% yield. The interplay between the 
bulky, electron-rich ligand (IAd), and a bulky organic base (pivalate) 
facilitates the highly challenging C(sp3)–H activation. In this case, the 
 
formation of the six-membered palladacycle makes the ring opening 
impossible (intermediate A, scheme 3). On the other side the seven-
membered ring (intermediate B, scheme 3) can either undergo reduc-
tive elimination to 18 or ring opening towards 19a or isomer 19b. The 
Charette group observed these pathways to be ligand dependent, 
which is supported by the results outlined herein.[14] 
The mono and bisthiazole electrophiles were synthesized next 
(Scheme 4), as they were found in 2 and 3. The electrophile 20b is 
known in the literature[20] and 20a was synthesized in two steps from 
the known aldehyde 21 (3 steps from literature).[21] 18 was reduced 
with sodium borohydride to the corresponding alcohol, and converted 
to chloride in presence of thionyl chloride. This procedure gives the de-
sired electrophile 20a in 80% yield over two steps (scheme 3).[20] 




To access the pyridone core, a one pot deprotection/ alkylation proto-
col was developed (Scheme 4). Pyridine 17 was treated with tetrabu-
tylammonium fluoride in THF at 50 °C to remove the 2-(trimethylsi-
lyl)ethyl protecting group and after cooling down to rt, the electro-
philes 20a and 20b were directly added to the reaction mixture. Single 
compounds were isolated for both cases, and the thermodynamically 
more stable N-alkylation was determined through 2D NMR spectros-
copy (HSQC, HMBC).[22] Saponification with lithium hydroxide in 
THF:water mixtures yielded the free acids 22 (91%, over two steps) 
and 23 (75%, over two steps). The removal of 3,4,5-trimethoxybenzyl 
protecting group was targeted next. The acid 22 showed no deprotec-
tion or decomposition in trifluoroacetic acid as solvent, but addition of 
trifluoromethanesulfonic acid (25 eq.) showed full deprotection to 22a 
as monitored by UHPLC-MS. This observation highlights the stability of 
22, and in particular the cyclopropyl group, towards acidic conditions. 
We further functionalized the acid 22 with N-Boc cadaverine under 
T3P-mediated coupling, followed by Boc and 3,4,5-trimethoxybenzyl 
removal using a combination of TFA and [bis(triluoroace-
toxy)iodo]benzene (PIFA) to yield 24 (47%, 2 steps). The addition of 
PIFA as oxidant was crucial for a smooth 3,4,5-TMB deprotection.[23] 
The additional amino functionality in 24 renders the compound more 
water soluble. Surprisingly, target cyclopropyl pyridone 24 resisted 
nucleophilic attack by deoxyadenosine, guanosine, and cysteine in wa-
ter monitored by UHPLC-MS. If these systems are sufficiently conju-
gated, ring opening of cyclopropyl by different nucleophiles like amines 
or water can occur [24], but 24 shows an unusual high stability under 
the evaluated conditions and is not fitting into the common experi-
mental observations of related electrophiles. 
In summary, we present a short and straightforward synthetic route to 
pyridones containing 1,6-Michael acceptors that are structurally re-
lated to precolibactin metabolites. En route, we developed a highly re-
gioselective tertiary C-H functionalization of the cyclopropyl ring, con-
tributing to its activation mode. Furthermore, a one-step protocol with 
selective N-alkylation after protecting group removal furnished the de-
sired Michael acceptor. Future studies might shed light into the biolog-
ical activity and chemical reactivity of this compounds. 
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